Hospira Reports Third-Quarter 20...(50.1 37.6 Other assets ...),Health

Date:10/27/2009

50.1 37.6 Other assets 67.0 53.2 -------- -------- Total Assets $5,614.2 $5,074.1 ======== ======== Liabilities and Shareholders' Equity Current Liabilities: Short-term borrowings $399.5 $338.3 Trade accounts payable 200.1 231.5 Salaries, wages and commissions 163.5 144.7 Deferred income taxes 0.1 1.5 Other accrued liabilities 412.8 331.5 -------- -------- Total Current Liabilities 1,176.0 1,047.5 -------- -------- Long-term debt 1,710.9 1,834.0 Deferred income taxes 23.1 25.2 Post-retirement obligations 167.1 195.5 Other long-term liabilities 92.0 195.5 Commitments and Contingencies -------- -------- Total Shareholders' Equity 2,445.1 1,776.4 -------- -------- Total Liabilities and Shareholders' Equity $5,614.2 $5,074.1 ======== ======== Hospira, Inc. Condensed Consolidated Statements of Cash Flows (Unaudited) (dollars in millions)
'/>"/>

SOURCE Hospira, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
Related medicine technology :

1. Hospira Acquires Worldwide Rights to Biogeneric Version of Filgrastim
2. Hospira Acquires Worldwide Rights to Biogeneric Version of Filgrastim and Manufacturing Facility From PLIVA
3. Hospira, Celltrion, Enter Business Cooperation Agreement to Develop and Market Biogeneric Drugs
4. Hospira to Present at Credit Suisse 18th Annual Healthcare Conference Nov. 11
5. Hospira Names Daphne E. Jones Chief Information Officer
6. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
7. Spherix Reports Second Quarter Earnings
8. Tapestry Reports Second Quarter 2007 Results
9. Callisto Reports on Second-Quarter 2007 Milestones
10. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
11. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs